Breast tumor cells with P13K mutation or HER2 amplification are selectively addicted to Akt signaling

PLoS ONE

Volumn 3, Issue 8, 2008, Pages

  She, Qing Bai ^a   Chandarlapaty, Sarat ^a   Ye, Qing ^a   Lobo, Jose ^a   Haskell, Kathleen M ^b   Leander, Karen R ^b   DeFeo Jones, Deborah ^b   Huber, Hans E ^b   Rosen, Neal ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; TRASTUZUMAB; DIMETHYL SULFOXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG SENSITIVITY; DRUG TOLERABILITY; ENZYME ACTIVATION; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPERINSULINEMIA; NONHUMAN; PROTEIN DEPLETION; SIGNAL TRANSDUCTION; TRANSIENT HYPERGLYCEMIA; TRANSIENT HYPERINSULINEMIA; TUMOR XENOGRAFT; BREAST TUMOR; CELL CYCLE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; BREAST NEOPLASMS; CELL CYCLE; DIMETHYL SULFOXIDE; FEMALE; G1 PHASE; GENE AMPLIFICATION; HUMANS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 52449092107     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003065     Document Type: Article

References (39)

1. Cantley LC (2002) The phosphoinesitide 3-kinase pathway. Science 296: 1655-1657.
2. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL (1998) The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 95: 15587-15591.
3. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
4. Hynes NE, Lane HA (2005) ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341-354.
5. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
6. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
7. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, et al. (2004) The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3: 772-775.
8. Li J, Yen G, Liaw D, Podsypanina K, Bose S, et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.
9. Garcia JM, Silva J, Pena C, Garcia V, Rodriguez R, et al. (2004) Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer 41: 117-124.
10. Wang X, Trotman LC, Koppie T, Alimonti A, Chen Z, et al. (2007) NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128: 129-139.
11. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.
12. Saal LH, Holm K, Maurer M, Memeo L, Su T, et al. (2005) PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65: 2554-2559.
13. Hellyer NJ, Cheng K, Koland JG (1998) ErbB 3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem J 333(Pt 3): 757-763.
14. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF 3rd, et al. (2003) The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A 100: 8933-8938.
15. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, et al. (2007) Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A 104: 7564-7569.
16. Majumder PK, Yeh JJ, George DJ, Febbo PG, Kum J, et al. (2003) Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A 100: 7841-7846.
17. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, et al. (1992) AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A 89: 9267-9271.
18. Carpten JQ, Faber AL, Horn C, Donoho GP, Briggs SL, et al. (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448: 439-444.
19. LoPiccolo J, Granville CA, Gills JJ, Dennis PA (2007) Targeting Akt in cancer therapy. Anticancer Drugs 18: 861-874.
20. Lindsley CW, Barnett SF, Layton ME, Bilodeau MT (2008) The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. Curr Cancer Drug Targets 8: 7-18.
21. Bilodeau MT, Balitza AE, Hoffman JM, Manley PJ, Barnett SF, et al. (2008) Allosteric inhibitors of Akt1 and Akt2: A naphthyridinone with efficacy in an A2780 tumor xenograft model. Bioorg Med Chem Lett 18: 3178-3182.
22. Barnett SF, Defeo-Jones D, Fu S, Hancock PJ, Haskell KM, et al. (2005) Identification and characterization of pleckstrin-homology-dormin-dependent and isoenzyme-specific Akt inhibitors. Biochem J 385: 399-408.
23. DeFeo-Jones D, Barnett SF, Fu S, Hancock PJ, Haskell KM, et al. (2005) Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol Cancer Ther 4: 271-279.
24. Lacroix M, Leclercq G (2004) Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat 83: 249-289.
25. Weng LP, Smith WM, Dahia. PL, Ziebold U, Gil E, et al. (1999) PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. Cancer Res 59: 5808-5814.
26. Tschopp O, Yang ZZ, Brodbeck D, Dummler BA, Hemmings-Mieszczak M, et al. (2005) Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis. Development 132: 2943-2954.
27. Robertson GP (2005) Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev 24: 273-285.
28. She QB, Solit DB, Ye Q, O'Reilly KE, Lobo J, et al. (2005) The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8: 287-297.
29. Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q et al. (2001) Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292: 1728-1731.
30. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792.
31. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, et al. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Glin Oncol 17: 2639-2648.
32. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719-726.
33. Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, et al. (2008) Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 26: 1066-1072.
34. Finkle D, Quan ZR, Asghari V, Kloss J, Chaboosi N, et al. (2004) HER2-targeted therapy reduces incidence and progression ofmidlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice. Clin Cancer Res 10: 2499-2511.
35. Weinstein IB (2002) Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297: 63-64.
36. Sharma SV, Settleman J (2007) Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 21: 3214-3231.
37. Butler M, McKay RA, Popoff IJ, Gaarde WA, Witchell D, et al. (2002) Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes 51: 1028-1084.
38. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508.
39. Nusse M, Beisker W, Hoffmann C, Tarnok A (1990) Flow cytometric analysis of G1- and G2/M-phase subpopulations in mammalian cell nuclei using side scatter and DNA content measurements. Cytometry 11: 813-821.